CD59 gene therapy

Drug Profile

CD59 gene therapy

Alternative Names: Membrane attack complex inhibitor factor gene therapy

Latest Information Update: 25 Nov 2003

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action CD59 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 17 Mar 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 30 Dec 2000 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)
  • 30 Dec 2000 Discontinued - Preclinical for Transplant rejection in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top